Analysts Conflicted on These Healthcare Names: Align Tech (ALGN) and Boston Scientific (BSX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Align Tech (ALGN – Research Report) and Boston Scientific (BSX – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Align Tech (ALGN)
Morgan Stanley analyst Erin Wright maintained a Hold rating on Align Tech today and set a price target of $169.00. The company’s shares closed last Wednesday at $161.30, close to its 52-week low of $157.57.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
Currently, the analyst consensus on Align Tech is a Moderate Buy with an average price target of $192.20, a 22.2% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $170.00 price target.
See the top stocks recommended by analysts >>
Boston Scientific (BSX)
Morgan Stanley analyst Patrick Wood maintained a Buy rating on Boston Scientific today and set a price target of $118.00. The company’s shares closed last Wednesday at $75.50.
According to TipRanks.com, Wood is a 3-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $108.00, implying a 32.7% upside from current levels. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.
